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Getting to the Core of the Matter*Pamela S. Douglas, MD,y Rebecca T. Hahn, MDzSEE PAGE 1364T he science and practice of rigorous quantita-tive echocardiography has never been moreimportant than in the era of transcatheter
treatment of structural heart disease and speciﬁcally
transcatheter aortic valve replacement (TAVR).
Indeed, one of the most important roles of echocardi-
ography is in clinical trials of devices for TAVR, which
require serial noninvasive measurements to fully
judge the long-term hemodynamic effects of thera-
peutic interventions and lend insight into the mecha-
nism of those changes. In addition to overseeing
imaging acquisition and measurement, the echocar-
diographic core laboratory (ECL) ideally plays an
essential role in trial design and conduct, statistical
design, and sample size by reducing the variability
of measurements (1,2). The quality of the ECL
thus is essential to the scientiﬁc credibility of trials
including imaging endpoints.
An important secondary goal of performing
a comprehensive echocardiographic assessment of
cardiac structure, function, and hemodynamics is
insights into mechanisms of a particular ﬁnding. Prior
reports from the CoreValve U.S. Pivotal Trial (Safety
and Efﬁcacy Study of the Medtronic CoreValve Sys-
tem in the Treatment of Symptomatic Severe Aortic
Stenosis in High Risk and Very High Risk Subjects
Who Need Aortic Valve Replacement) suggested that
patients surviving to 1 year experienced signiﬁcant
regression of paravalvular regurgitation (PVAR) (3),*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
From the yDuke Clinical Research Institute and Duke University Medical
Center, Durham, North Carolina; and the zColumbia University Medical
Center/New York Presbyterian Hospital, New York, New York. Dr.
Douglas has received institutional research grants from Edwards
Lifesciences. Dr. Hahn has received institutional research grants from
Edwards Lifesciences; and has a relationship with the core laboratory
for the PARTNER trial.a surprising ﬁnding without a clear etiology. By
contrast, most previous studies reported no change
in gradients, valve area, or PVAR with the self-
expanding valve (4–7). In this issue of iJACC, Oh
et al. (8) report the 1-year echocardiographic ﬁndings
of the CoreValve U.S. Pivotal Trial, including a
detailed dissection of valve size and function. In
addition to supporting the main study, their careful
attention to image and measurement quality provides
interesting new data suggesting a possible etiology
for PVAR regression.Oh et al. (8) conﬁrm that 44% of patients showed
a $1 grade improvement in PVAR at 1 year, whereas
18% had worsening of PVAR. These ﬁndings are
not dissimilar to the reported 2-year results of the
PARTNER IA (Placement of Aortic Transcatheter
Valves 1A) trial in which PVAR improved in 31.9% and
worsened in 22.7% of patients (9). Oh et al. (8) also
report a 1-year decrease in peak and mean transaortic
gradients and a statistically, but not clinically, sig-
niﬁcant 5% increase in effective oriﬁce area
compared with baseline (from 1.78  0.51 cm2 to
1.87  0.54 cm2). In addition, there were signiﬁcant,
although small, increases in left ventricular diastolic
and systolic volumes and stroke volume, which
would seem to argue against a signiﬁcant reduction
in regurgitant volumes. The authors offer 3 possible
explanations for their ﬁndings: 1) variability in
echocardiographic measurement; 2) increase in
stroke volume; and 3) gradual remodeling due to
self-expansion of the CoreValve (Medtronic, Minne-
apolis, Minnesota).
The third possible etiology could nicely explain
both the increased effective oriﬁce area and
PVAR regression, but hinges on the ability to ac-
curately measure the reported mean change in left
ventricular outﬂow tract (LVOT) diameter of only
0.08 cm; reported interobserver variability for this
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1377measurement is 4.8  4.1% (10), or roughly 0.1 cm.
Further, the inﬂow frame of the self-expanding valve is
typically elliptical (11), and the assessment of LVOT at
the outer-to-outer edges of the transcatheter valve
may be signiﬁcantly inﬂuenced by slight changes in
coaxiality of the imaging plane to the implanted valve.
Nonetheless, along with a ﬂow-dependent increase in
valve area with increased stroke volume, a gradual
expansion of the CoreValve cannot entirely be
excluded. This is supported by in vitro studies of the
CoreValve (12) showing that the radial force of
this valve is essentially dependent on the diameter
of the LVOT.
As with all post-hoc analyses of subgroups, results
must be interpreted cautiously. Although Oh et al. (8)
are to be congratulated on performing paired ana-
lyses, missing data may skew results because only 272
patients (47%) had complete echocardiographic data
analyzable (Online Table 2); the analysis of PVAR in
this small subgroup was not reported. Moreover,
given the 3-dimensional shape of this valve and its
complex interaction with an elliptical LVOT and
annulus, 2-dimensional echocardiography may not be
the ideal measurement tool to test this hypothesis,
and deﬁnitive proof of valve expansion may require
3-dimensional imaging modalities.
Despite these concerns, Oh et al. (8) clearly
reconﬁrm the value that can be provided by a pro-
spective investment in high-quality image acquisition
and assessment using an experienced and meticulous
ECL (8). Trials that do not “hardwire” the need
for imaging standardization, quality, and reproduc-
ibility into their design provide cautionary lessons.
The PROSPECT (Predictors of Response to Cardiac
Resynchronization Therapy) trial failed to ﬁnd an
echocardiographic predictor of cardiac resynchroni-
zation therapy response in part because of exclusion
of large portions of data due to suboptimal quality
and a multivendor, multicore lab methodology that
resulted in high variability with lack of agreement
between ECLs (13,14). Intercore lab variability in
methodology has also played an important role in
the disparate reports of PVAR between the ﬁrst and
second PARTNER trials (15).
In response to trials such as these, the American
Society of Echocardiography deﬁned best practicesfor ECLs in an expert consensus statement “Echocar-
diographic Imaging in Clinical Trials” (16). Two
essential components, site submission of adequate
data and accurate/reproducible ECL measurements,
can drive the success of a trial. The STICH (Surgical
Treatment for Ischemic Heart Failure) trial results
emphasized the difﬁculty in acquiring adequate im-
aging for endpoint analysis (17). In this heart failure
trial, only 43.5% of 2,006 patients had adequate
imaging for biplane calculation of volumes and ejec-
tion fraction.
The PARTNER trials serve as “case examples” of
implantation of ECL best practices, with rigorous
monitoring of site image acquisition quality, consis-
tency in image analysis, and image analysis quality
monitoring (18). The ECLs provide sites with feedback
on each study, supplemented by benchmarked quar-
terly “report cards” and remedial training. Using
these continuous quality improvement methods, 88%
of studies had measureable biplane volumes in the
SAPIEN 3 registry of the PARTNER II trial (unpub-
lished data), and interobserver and intraobserver
variability of 8 critical variables were all $0.90
(intraclass correlation coefﬁcient) (18). PVAR was
assessed using a multiwindow, multiparametric,
integrative approach, as advocated by Pibarot et al.
(19). Oh et al. (8) clearly follow these precepts. In
addition, in the present study, Oh et al. (8) demon-
strate that thoughtful interpretation of the data is
required, including an understanding of the limita-
tions of the technology and statistical methodology.
Because the value of echocardiography in large clin-
ical trials is dependent on maintaining quality in data
acquisition and analysis, this should remain a pri-
mary goal for all core laboratories. As echocardio-
graphic advances such as strain imaging and 3-
dimensional imaging are added to the armamen-
tarium, and the role of ECLs in trial design and
implementation expands, the value provided to large
clinical trials can only increase.
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